Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 15/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891884 | 1.00 | HPGDS (0.46) | HPGDSPDGFRBPDGFRAEGFRCYP17A1 | |
| SCHEMBL1896413 | 0.83 | ABCB11 (0.53) | CYP17A1CYP2C9CYP2C19ABCB11 | |
| SCHEMBL1896411 | 0.83 | ABCB11 (0.53) | CYP17A1CYP2C9CYP2C19ABCB11 | |
| SCHEMBL9071489 | 0.75 | HPGDS (0.56) | HPGDSPDGFRBPDGFRAEGFRABCB11 | |
| SCHEMBL1891721 | 0.74 | CYP2C9 (0.36) | CYP17A1CYP2C9CYP2C19ABCB11 | |
| SCHEMBL1891723 | 0.74 | CYP2C9 (0.36) | CYP17A1CYP2C9CYP2C19ABCB11 | |
| SCHEMBL1892127 | 0.74 | SLC2A1 (0.47) | HPGDSCYP2C9CYP2C19 | |
| SCHEMBL1892130 | 0.74 | SLC2A1 (0.47) | HPGDSCYP2C9CYP2C19 | |
| SCHEMBL28808959 | 0.70 | HPGDS (0.65) | HPGDSPDGFRBPDGFRAEGFRCYP2C9 | |
| SCHEMBL4371627 | 0.69 | HPGDS (0.59) | HPGDSPDGFRBPDGFRAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935713-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090105310-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105310-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use | GCGR, GLP1R, GPR119 | HPGDS 570/4885PDGFRB 691/4885PDGFRA 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.